STOCK TITAN

[Form 4] Omeros Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

U.S. Physical Therapy, Inc. (NYSE: USPH) filed a Form 8-K dated July 1, 2025 under Item 7.01 (Regulation FD Disclosure). The company reports that Barrington Research Associates, Inc. released a research report on the same day that contains information attributed to USPH management. That report is furnished as Exhibit 99.1. In accordance with SEC rules, the company specifies that the material is being furnished, not filed; therefore it is not subject to Section 18 liability and is not incorporated by reference into Securities Act filings. No financial statements, earnings figures, transactions, or guidance updates accompany this filing.

U.S. Physical Therapy, Inc. (NYSE: USPH) ha presentato un modulo 8-K datato 1 luglio 2025 ai sensi del Punto 7.01 (Divulgazione ai sensi del Regolamento FD). La società comunica che Barrington Research Associates, Inc. ha pubblicato lo stesso giorno un rapporto di ricerca contenente informazioni attribuite al management di USPH. Tale rapporto è fornito come Allegato 99.1. In conformità alle norme della SEC, la società specifica che il materiale è fornito, non depositato; pertanto non è soggetto alla responsabilità ai sensi della Sezione 18 e non è incorporato per riferimento nelle dichiarazioni ai sensi del Securities Act. Nessun bilancio, risultato economico, transazione o aggiornamento sulle previsioni accompagna questa comunicazione.

U.S. Physical Therapy, Inc. (NYSE: USPH) presentó un Formulario 8-K fechado el 1 de julio de 2025 bajo el Ítem 7.01 (Divulgación según Regulación FD). La compañía informa que Barrington Research Associates, Inc. publicó ese mismo día un informe de investigación que contiene información atribuida a la gerencia de USPH. Dicho informe se presenta como el Anexo 99.1. De acuerdo con las normas de la SEC, la empresa especifica que el material se está proporcionando, no presentando; por lo tanto, no está sujeto a responsabilidad bajo la Sección 18 y no se incorpora por referencia en las presentaciones bajo la Ley de Valores. Esta presentación no incluye estados financieros, cifras de ganancias, transacciones ni actualizaciones de pronósticos.

U.S. Physical Therapy, Inc. (NYSE: USPH)는 2025년 7월 1일자 8-K 양식항목 7.01 (Regulation FD 공개)에 따라 제출했습니다. 회사는 Barrington Research Associates, Inc.가 같은 날 USPH 경영진에 의해 제공된 정보를 포함한 연구 보고서를 발표했다고 보고했습니다. 해당 보고서는 증거자료 99.1로 제공됩니다. SEC 규정에 따라 이 자료는 제출된 것이 아니라 제공된 것임을 명시하며, 따라서 섹션 18 책임 대상이 아니며 증권법 제출서류에 참조로 포함되지 않습니다. 이 제출서류에는 재무제표, 수익 수치, 거래 또는 가이던스 업데이트가 포함되어 있지 않습니다.

U.S. Physical Therapy, Inc. (NYSE : USPH) a déposé un formulaire 8-K daté du 1er juillet 2025 conformément au point 7.01 (Divulgation Réglementation FD). La société informe que Barrington Research Associates, Inc. a publié le même jour un rapport de recherche contenant des informations attribuées à la direction de USPH. Ce rapport est fourni en tant que Pièce 99.1. Conformément aux règles de la SEC, la société précise que ce document est fourni, non déposé ; par conséquent, il n’est pas soumis à la responsabilité en vertu de la Section 18 et n’est pas incorporé par référence dans les dépôts au titre du Securities Act. Aucun état financier, chiffre de résultats, transaction ou mise à jour des prévisions n’accompagne ce dépôt.

U.S. Physical Therapy, Inc. (NYSE: USPH) reichte am 1. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Regulation FD Offenlegung) ein. Das Unternehmen berichtet, dass Barrington Research Associates, Inc. am selben Tag einen Forschungsbericht veröffentlicht hat, der Informationen enthält, die dem Management von USPH zugeschrieben werden. Dieser Bericht wird als Anlage 99.1 bereitgestellt. Gemäß den SEC-Vorschriften gibt das Unternehmen an, dass das Material bereitgestellt, nicht eingereicht wird; daher unterliegt es nicht der Haftung gemäß Abschnitt 18 und wird nicht durch Verweis in Wertpapiergesetz-Einreichungen aufgenommen. Dieser Einreichung liegen keine Finanzberichte, Gewinnzahlen, Transaktionen oder Prognoseaktualisierungen bei.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: USPH simply furnishes a third-party research report; no new financial metrics disclosed—neutral for valuation.

The 8-K serves mainly as a compliance vehicle. By furnishing Barrington’s report, management avoids selective disclosure risk and remains in line with Regulation FD. Because the filing lacks revenue, earnings, or guidance revisions, there is no immediate catalyst for the stock. Investors must read Exhibit 99.1 for any substantive insights, but those details are outside this 8-K. Overall market impact is expected to be negligible.

TL;DR: Filing reflects good disclosure hygiene but has limited strategic significance.

By furnishing the research report, USPH demonstrates transparency and mitigates Regulation FD exposure, a prudent governance step. However, because the document carries no actionable financial or operational data, its importance is procedural rather than material. The company also clarifies that the information is not deemed ‘filed,’ minimizing legal exposure. From a governance standpoint, this is standard practice and does not alter risk profiles.

U.S. Physical Therapy, Inc. (NYSE: USPH) ha presentato un modulo 8-K datato 1 luglio 2025 ai sensi del Punto 7.01 (Divulgazione ai sensi del Regolamento FD). La società comunica che Barrington Research Associates, Inc. ha pubblicato lo stesso giorno un rapporto di ricerca contenente informazioni attribuite al management di USPH. Tale rapporto è fornito come Allegato 99.1. In conformità alle norme della SEC, la società specifica che il materiale è fornito, non depositato; pertanto non è soggetto alla responsabilità ai sensi della Sezione 18 e non è incorporato per riferimento nelle dichiarazioni ai sensi del Securities Act. Nessun bilancio, risultato economico, transazione o aggiornamento sulle previsioni accompagna questa comunicazione.

U.S. Physical Therapy, Inc. (NYSE: USPH) presentó un Formulario 8-K fechado el 1 de julio de 2025 bajo el Ítem 7.01 (Divulgación según Regulación FD). La compañía informa que Barrington Research Associates, Inc. publicó ese mismo día un informe de investigación que contiene información atribuida a la gerencia de USPH. Dicho informe se presenta como el Anexo 99.1. De acuerdo con las normas de la SEC, la empresa especifica que el material se está proporcionando, no presentando; por lo tanto, no está sujeto a responsabilidad bajo la Sección 18 y no se incorpora por referencia en las presentaciones bajo la Ley de Valores. Esta presentación no incluye estados financieros, cifras de ganancias, transacciones ni actualizaciones de pronósticos.

U.S. Physical Therapy, Inc. (NYSE: USPH)는 2025년 7월 1일자 8-K 양식항목 7.01 (Regulation FD 공개)에 따라 제출했습니다. 회사는 Barrington Research Associates, Inc.가 같은 날 USPH 경영진에 의해 제공된 정보를 포함한 연구 보고서를 발표했다고 보고했습니다. 해당 보고서는 증거자료 99.1로 제공됩니다. SEC 규정에 따라 이 자료는 제출된 것이 아니라 제공된 것임을 명시하며, 따라서 섹션 18 책임 대상이 아니며 증권법 제출서류에 참조로 포함되지 않습니다. 이 제출서류에는 재무제표, 수익 수치, 거래 또는 가이던스 업데이트가 포함되어 있지 않습니다.

U.S. Physical Therapy, Inc. (NYSE : USPH) a déposé un formulaire 8-K daté du 1er juillet 2025 conformément au point 7.01 (Divulgation Réglementation FD). La société informe que Barrington Research Associates, Inc. a publié le même jour un rapport de recherche contenant des informations attribuées à la direction de USPH. Ce rapport est fourni en tant que Pièce 99.1. Conformément aux règles de la SEC, la société précise que ce document est fourni, non déposé ; par conséquent, il n’est pas soumis à la responsabilité en vertu de la Section 18 et n’est pas incorporé par référence dans les dépôts au titre du Securities Act. Aucun état financier, chiffre de résultats, transaction ou mise à jour des prévisions n’accompagne ce dépôt.

U.S. Physical Therapy, Inc. (NYSE: USPH) reichte am 1. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Regulation FD Offenlegung) ein. Das Unternehmen berichtet, dass Barrington Research Associates, Inc. am selben Tag einen Forschungsbericht veröffentlicht hat, der Informationen enthält, die dem Management von USPH zugeschrieben werden. Dieser Bericht wird als Anlage 99.1 bereitgestellt. Gemäß den SEC-Vorschriften gibt das Unternehmen an, dass das Material bereitgestellt, nicht eingereicht wird; daher unterliegt es nicht der Haftung gemäß Abschnitt 18 und wird nicht durch Verweis in Wertpapiergesetz-Einreichungen aufgenommen. Dieser Einreichung liegen keine Finanzberichte, Gewinnzahlen, Transaktionen oder Prognoseaktualisierungen bei.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cancelmo Peter B

(Last) (First) (Middle)
201 ELLIOTT AVENUE WEST

(Street)
SEATTLE WA 98119

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
OMEROS CORP [ OMER ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP, General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $3.2 06/30/2025 A 100,000 (1) 06/30/2035 Common Stock 100,000 $0 100,000 D
Explanation of Responses:
1. This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2025. Installments vest and become exercisable on each monthly anniversary thereafter.
/s/ Peter B. Cancelmo 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did USPH disclose in its July 1, 2025 Form 8-K?

The company furnished a Barrington Research Associates report that contains information attributed to management.

What is Exhibit 99.1 in the USPH 8-K filing?

Exhibit 99.1 is the full research report issued by Barrington Research Associates on July 1, 2025.

Does the filing include any financial results or guidance?

No. The 8-K contains no revenue, earnings, or forward-looking guidance figures.

Is the Barrington report considered "filed" with the SEC?

No. It is merely "furnished," meaning it is not subject to Section 18 liability and is not incorporated into other SEC filings.

Why did USPH furnish the research report under Item 7.01?

To comply with Regulation FD by making information shared with a third party broadly available to all investors.
Omeros

NASDAQ:OMER

OMER Rankings

OMER Latest News

OMER Latest SEC Filings

OMER Stock Data

187.50M
56.02M
4.45%
46.16%
15.92%
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE